To include your compound in the COVID-19 Resource Center, submit it here.

Aldeyra gains on Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $1.40 (33%) to $5.65 on Tuesday after reporting that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE